Compare WING & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WING | GPCR |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.3B |
| IPO Year | 2015 | 2023 |
| Metric | WING | GPCR |
|---|---|---|
| Price | $246.33 | $64.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 11 |
| Target Price | ★ $339.88 | $104.64 |
| AVG Volume (30 Days) | ★ 1.1M | 796.4K |
| Earning Date | 05-22-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 6.21 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $19.88 | N/A |
| Revenue Next Year | $16.90 | N/A |
| P/E Ratio | $38.31 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $204.09 | $13.24 |
| 52 Week High | $388.14 | $94.90 |
| Indicator | WING | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 34.74 |
| Support Level | $227.67 | $60.42 |
| Resistance Level | $276.53 | $72.00 |
| Average True Range (ATR) | 18.07 | 3.49 |
| MACD | -0.76 | -1.15 |
| Stochastic Oscillator | 33.71 | 20.98 |
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.